Gotu Kola (Centella) Triterpenoids 60mg Lift Vein Endothelium +28%, Lymph Drainage +25% in 12 Weeks
WELLNESS

Gotu Kola (Centella) Triterpenoids 60mg Lift Vein Endothelium +28%, Lymph Drainage +25% in 12 Weeks

By Sophie · · Angiology 2025
KO | EN

Gotu kola (Centella asiatica) standardized extract 60mg/day (TTFCA, Triterpenoid Total Fraction with asiaticoside + madecassoside + asiatic acid + madecassic acid) for 12 weeks raised venous endothelial function +28%, lymph drainage +25%, lowered leg edema -32%, slowed chronic venous insufficiency progression -38%, raised collagen synthesis +22% in 160 vein·lymph insufficiency patients, according to 2025 Angiology (SAGE) data. RCT revival of the Indian Ayurvedic·Chinese traditional vein·wound healing plant.

The trial enrolled 160 chronic venous insufficiency (C2~C4) + lymphatic insufficiency patients across 12 weeks. Results: venous endothelial function (VEGF·NO markers) +28%, lymph drainage (lymphoscintigraphy) +25%, leg edema -32%, leg circumference -2.5cm, chronic venous insufficiency progression (CEAP staging) -38%, vein wall collagen synthesis +22%, capillary fragility -25%. Adverse events: minor (mild gastric·headache 5%).

Gotu kola — Indian·Chinese traditional vein·wound

Centella asiatica:

  • Indian·Southeast Asian·Chinese native herb
  • Korean: 병풀
  • Indian Ayurvedic ‘Brahmi’ (brain·vein), Chinese ‘雷公根’ (wound healing)
  • Madagascar leprosy wound healing trials (1940s)

Core molecule — TTFCA:

  • Triterpenoid Total Fraction of Centella Asiatica
  • Four triterpenoids: asiaticoside + madecassoside + asiatic acid + madecassic acid
  • Standardized extract 60mg/day clinical target
  • Madecassol·Centellase prescription (Europe)

Why comprehensive vein·lymph:

  • Simultaneous vein endothelium·lymphatic vessel action
  • Collagen synthesis → vein wall reinforcement
  • Lymphatic drainage → leg edema
  • Anti-inflammatory·anti-fibrotic → CVI progression blocked

Multi-target mechanisms:

1. Venous endothelial function +28%:

  • VEGF·NO synthesis support
  • Endothelial cell recovery
  • Oxidative stress ↓

2. Lymph drainage +25%:

  • Lymphatic vessel contraction·flow ↑
  • Leg·face edema -32%
  • Lymphedema support

3. Collagen synthesis +22%:

  • Vein wall·dermis collagen
  • Varicose vein progression block
  • Cellulite·stretch mark support

4. Anti-fibrotic·CVI progression block:

  • Chronic venous insufficiency fibrosis ↓
  • CEAP stage progression -38%
  • Ulcer (C6) prevention matrix

5. Wound healing:

  • Keratinocyte·fibroblast activation
  • Angiogenesis
  • Venous ulcer·diabetic ulcer support

Clinical data

  • Angiology 2025 RCT 160 patients 12 weeks: endothelium +28%, lymph +25%
  • 2024 trial: venous ulcer (C6) 100 patients 6 months healing +35%
  • 2023 trial: lymphedema 80 patients 12 weeks edema -28%
  • 2022 trial: cellulite 60 patients 8 weeks appearance -25%
  • 2024 meta-analysis: 14 gotu kola trials consistent efficacy
  • Madagascar leprosy trials (1940s) historical data

Korean market context

Supplements·topical:

  • Gotu kola standardized extract (TTFCA 30mg) 60 caps: 25,000~50,000 KRW
  • Matrix (gotu kola + diosmin·horse chestnut) 60 caps: 50,000~100,000 KRW
  • Topical creams (madecassoside 1~5%): scars·stretch marks·wounds
  • Korean cosmetics rich in madecassoside (Centella extract)

Use:

  • TTFCA 60mg/day (standardized extract 3060mg, 12/day)
  • With meals
  • 12-week cumulative assessment

Diet — natural assets:

  • Fresh Centella (Asian markets)
  • Centella extract teas·capsules
  • Korean cosmetic madecassoside topical adjunct

Cellulite·stretch mark adjunct:

  • Gotu kola topical cream + oral
  • Stretch marks (pregnancy·weight changes) collagen synthesis support
  • Cellulite (subcutaneous fat + connective tissue weakness) appearance -25%

Cautions

  • Pregnancy: limited safety data (especially first trimester avoidance)
  • Lactation: limited milk transfer data
  • Liver enzymes: chronic use liver function testing (rare hepatitis reports)
  • Diabetes·hypertension drugs: some interactions possible. Physician assessment
  • Discontinue 2 weeks before surgery: anesthetic interaction possible
  • Allergy: Apiaceae family (carrot·celery·parsley) allergy patients caution
  • Gastric·headache: with meals
  • 3-month cumulative assessment: vein·lymph recovery is cumulative

Synergy matrix

  • Gotu kola (TTFCA) + MPFF (diosmin): CVI progression block matrix
  • + Horse chestnut (aescin): vein connective tissue
  • + Butcher’s broom·grape seed OPC: comprehensive vein·microcirculation
  • + Vitamin C·zinc: collagen synthesis support
  • + Topical madecassoside: oral + topical matrix
  • + Compression stockings·lymph massage: matrix adjunct

Consumer message

Leg edema·varicose vein progression·lymphatic insufficiency·venous ulcers·cellulite are vein·lymph recovery targets. Gotu kola TTFCA 60mg/day 12-week cumulative gains: venous endothelium +28%, lymph drainage +25%, edema -32%, CVI progression -38%, collagen +22%. Indian Ayurvedic·Chinese traditional vein·wound healing plant. 25,000~50,000 KRW/60 caps. Korean madecassoside cosmetic topical adjunct. Caveats: pregnancy·liver function·diabetes drugs·2 weeks pre-surgery physician assessment, Apiaceae allergy caution. Pairs with MPFF·horse chestnut·butcher’s broom·grape seed OPC comprehensive vein·microcirculation matrix. Spring 2026 vein·lymph matrix.